Skip to main content

Results on the interactome: around 30 approved drugs may show activity against coronavirus




Press & Communications Section Head
Tel.+34 93 40 37255

Several media have published an interview with Patrick Aloy, head of the Structural Bioinformatics and Network Biology Lab at IRB Barcelona, in which he talks about a study being done by scientists at the University of California. This study analyses the physical interactions of the coronavirus in order to understand how this virus “sequesters” our proteins to ensure its survival. This research aims to find drugs that can act against these proteins. In this regard, the researchers at the University of California have found 70 compounds, including around 30 drugs authorized by the US Food and Drug Agency(FDA).

Aloy explains that the strategy to look for pharmacological targets among the human proteins with which the virus interacts is pertinent since, among other factors, the virus has very few of its own proteins. However, he goes on to say that there is still a long way to go before a cure can be found.


Link to: Agencia SINC

Link to: Voz Populi

Link to: iLeon

Link to: Herencia genética y



About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).